Ikena presents preclinical data for IK-930 with TEAD1 selectivity and wider therapeutic window vs panTEAD

ImageneBio, Inc.

IK-930 selectively inhibits TEAD1 with equivalent antitumor activity to panTEAD inhibitors but no renal toxicity in monkeys at any tested dose.
Average urinary protein-to-creatinine ratios and histopathology predicted a therapeutic index <1 for panTEAD vs broad window for IK-930.
IK-930 plus osimertinib delayed emergence of drug-tolerant persister cells in preclinical EGFR-mutant NSCLC models.
Phase 1 monotherapy dose escalation ongoing; initial monotherapy clinical data expected in 2H 2023.
Cash >$155M as of filing; runway into 2025; partnered IK-175 with BMS potentially $50M opt-in fees by early 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.